The presentation will address two topics related to licensing efforts of the National Cancer Institute (NCI). The first, a case study on the CAR-T product axicabtagene ciloleucel (sold under the brand name Yescarta®), will cover the development history of this ground-breaking therapy from the NCI technology transfer perspective. The second will be a brief discussion of NCI’s exclusive licensing practices as they concern important technologies in the adoptive cell therapy space. This will touch on how the NCI leverages federal licensing statute (e.g., 37 CFR § 404) to maximize utilization and public benefit of these inventions.
Speaker: Andrew Burke, Senior Technology Transfer Manager, National Cancer Institute
Read more & register!